149 related articles for article (PubMed ID: 15173275)
1. Re: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.
Ratliff B; Dietze EC; Bean GR; Moore C; Wanko S; Seewaldt VL
J Natl Cancer Inst; 2004 Jun; 96(11):883; author reply 884-5. PubMed ID: 15173275
[No Abstract] [Full Text] [Related]
2. Re: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.
Ponzone R; Biglia N; Sismondi P
J Natl Cancer Inst; 2004 Jun; 96(11):883-4; author reply 884-5. PubMed ID: 15173274
[No Abstract] [Full Text] [Related]
3. Re: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.
Lien EA; Ueland PM; Lønning PE
J Natl Cancer Inst; 2004 Jun; 96(11):884; author reply 884-5. PubMed ID: 15173277
[No Abstract] [Full Text] [Related]
4. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.
Stearns V; Johnson MD; Rae JM; Morocho A; Novielli A; Bhargava P; Hayes DF; Desta Z; Flockhart DA
J Natl Cancer Inst; 2003 Dec; 95(23):1758-64. PubMed ID: 14652237
[TBL] [Abstract][Full Text] [Related]
5. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment.
Jin Y; Desta Z; Stearns V; Ward B; Ho H; Lee KH; Skaar T; Storniolo AM; Li L; Araba A; Blanchard R; Nguyen A; Ullmer L; Hayden J; Lemler S; Weinshilboum RM; Rae JM; Hayes DF; Flockhart DA
J Natl Cancer Inst; 2005 Jan; 97(1):30-9. PubMed ID: 15632378
[TBL] [Abstract][Full Text] [Related]
6. Multicenter phase II feasibility trial of high-dose tamoxifen in patients with refractory or relapsed multiple myeloma.
Decaudin D; Etienne MC; De Cremoux P; Maciorowski Z; Vantelon JM; Voog E; Urien S; Tran-Perennou C; Renée N; Vielh P; Némati F; Pouillart P
J Natl Cancer Inst; 2004 Apr; 96(8):636-7. PubMed ID: 15100346
[No Abstract] [Full Text] [Related]
7. Tamoxifen pharmacogenetics moves closer to reality.
Garber K
J Natl Cancer Inst; 2005 Mar; 97(6):412-3. PubMed ID: 15770000
[No Abstract] [Full Text] [Related]
8. A hot flash on tamoxifen metabolism.
Goetz MP; Loprinzi CL
J Natl Cancer Inst; 2003 Dec; 95(23):1734-5. PubMed ID: 14652227
[No Abstract] [Full Text] [Related]
9. Tamoxifen, antidepressants, and CYP2D6: the conundrum continues.
Holzman D
J Natl Cancer Inst; 2009 Oct; 101(20):1370-1. PubMed ID: 19797723
[No Abstract] [Full Text] [Related]
10. Selective serotonin reuptake inhibitors and adjuvant tamoxifen therapy: risk of breast cancer recurrence and mortality.
Cronin-Fenton D; Lash TL; Sørensen HT
Future Oncol; 2010 Jun; 6(6):877-80. PubMed ID: 20528223
[No Abstract] [Full Text] [Related]
11. Augmentation of Endoxifen Exposure in Tamoxifen-Treated Women Following SSRI Switch.
Binkhorst L; Bannink M; de Bruijn P; Ruit J; Droogendijk H; van Alphen RJ; den Boer TD; Lam MH; Jager A; van Gelder T; Mathijssen RH
Clin Pharmacokinet; 2016 Feb; 55(2):249-55. PubMed ID: 26446141
[TBL] [Abstract][Full Text] [Related]
12. Paroxetine approval.
Mahon SM; Kaplan M
Am J Nurs; 2014 Jan; 114(1):10. PubMed ID: 24370506
[No Abstract] [Full Text] [Related]
13. [New antidepressive agents].
LaBranche S
Union Med Can; 1995 Nov; 124(3):8-13. PubMed ID: 8560639
[No Abstract] [Full Text] [Related]
14. The Risk of QTc-Interval Prolongation in Breast Cancer Patients Treated with Tamoxifen in Combination with Serotonin Reuptake Inhibitors.
Hussaarts KGAM; Berger FA; Binkhorst L; Oomen-de Hoop E; van Leeuwen RWF; van Alphen RJ; Mathijssen-van Stein D; de Groot NMS; Mathijssen RHJ; van Gelder T
Pharm Res; 2019 Dec; 37(1):7. PubMed ID: 31845095
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the neuropharmacodynamics of paroxetine in vivo utilizing microdialysis.
Ramaiya A; Johnson JH; Karnes HT
J Pharm Sci; 1997 Dec; 86(12):1497-500. PubMed ID: 9423168
[TBL] [Abstract][Full Text] [Related]
16. Orally administered endoxifen is a new therapeutic agent for breast cancer.
Ahmad A; Ali SM; Ahmad MU; Sheikh S; Ahmad I
Breast Cancer Res Treat; 2010 Jul; 122(2):579-84. PubMed ID: 20052538
[TBL] [Abstract][Full Text] [Related]
17. Endoxifen, the active metabolite of tamoxifen, is a substrate of the efflux transporter P-glycoprotein (multidrug resistance 1).
Teft WA; Mansell SE; Kim RB
Drug Metab Dispos; 2011 Mar; 39(3):558-62. PubMed ID: 21148080
[TBL] [Abstract][Full Text] [Related]
18. Potential interaction between isoniazid and selective serotonin-reuptake inhibitors.
Evans ME; Kortas KJ
Am J Health Syst Pharm; 1995 Oct; 52(19):2135-6. PubMed ID: 8535949
[No Abstract] [Full Text] [Related]
19. Tamoxifen metabolism in breast cancer treatment: Taking the focus off the CYP2D6 gene.
Novillo A; Romero-Lorca A; Gaibar M; Rubio M; Fernández-Santander A
Pharmacogenomics J; 2017 Mar; 17(2):109-111. PubMed ID: 27698402
[No Abstract] [Full Text] [Related]
20. Unjustified prescribing of CYP2D6 inhibiting SSRIs in women treated with tamoxifen.
Binkhorst L; Mathijssen RH; van Herk-Sukel MP; Bannink M; Jager A; Wiemer EA; van Gelder T
Breast Cancer Res Treat; 2013 Jun; 139(3):923-9. PubMed ID: 23760858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
